Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Anderson

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|July 1, 1992
Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administrationP M Anderson, E Katsanis, S F Sencer, et al.
Journal of Bacteriology|September 1, 1994
Expression of proteins encoded by the Escherichia coli cyn operon: carbon dioxide-enhanced degradation of carbonic anhydraseE I Kozliak, M B Guilloton, M Gerami-Nejad, et al.
Biochemistry|June 30, 1987
Interaction of mono- and dianions with cyanase: evidence for apparent half-site bindingP M Anderson, W V Johnson, J A Endrizzi, et al.
Cancer|March 27, 2001
Phase I study of CI-958 in children and adolescents with recurrent solid tumorsC A Arndt, M D Krailo, W Liu-Mares, et al.
The Journal of Biological Chemistry|February 25, 1992
Carbonic anhydrase in Escherichia coli. A product of the cyn operonM B Guilloton, J J Korte, A F Lamblin, et al.
Cancer|April 1, 1997
Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastasesC Khanna, P M Anderson, D E Hasz, et al.
International Immunopharmacology|January 29, 2002
Interleukin-2 liposomes for primary immune deficiency using the aerosol routeR M Ten, P M Anderson, N N Zein, et al.
Blood|June 15, 1997
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting propertiesJ L Hornick, L A Khawli, P Hu, et al.
Blood|December 1, 1992
G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cellsP M Anderson, W Crist, D Hasz, et al.
ESMO Open|July 30, 2023
Sodium fluoride (Na<sup>18</sup>F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumorsK Kairemo, M A Gouda, L Buschhorn, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|July 1, 1992
Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administrationP M Anderson, E Katsanis, S F Sencer, et al.
Journal of Bacteriology|September 1, 1994
Expression of proteins encoded by the Escherichia coli cyn operon: carbon dioxide-enhanced degradation of carbonic anhydraseE I Kozliak, M B Guilloton, M Gerami-Nejad, et al.
Biochemistry|June 30, 1987
Interaction of mono- and dianions with cyanase: evidence for apparent half-site bindingP M Anderson, W V Johnson, J A Endrizzi, et al.
Cancer|March 27, 2001
Phase I study of CI-958 in children and adolescents with recurrent solid tumorsC A Arndt, M D Krailo, W Liu-Mares, et al.
The Journal of Biological Chemistry|February 25, 1992
Carbonic anhydrase in Escherichia coli. A product of the cyn operonM B Guilloton, J J Korte, A F Lamblin, et al.
Cancer|April 1, 1997
Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastasesC Khanna, P M Anderson, D E Hasz, et al.
International Immunopharmacology|January 29, 2002
Interleukin-2 liposomes for primary immune deficiency using the aerosol routeR M Ten, P M Anderson, N N Zein, et al.
Blood|June 15, 1997
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting propertiesJ L Hornick, L A Khawli, P Hu, et al.
Blood|December 1, 1992
G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cellsP M Anderson, W Crist, D Hasz, et al.
ESMO Open|July 30, 2023
Sodium fluoride (Na<sup>18</sup>F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumorsK Kairemo, M A Gouda, L Buschhorn, et al.
Pageof 12